glp 1 agonists contraindications What are the to starting Glucagon-like peptide-1 (GLP-1) receptor agonist therapy? New video coming on Incretins

physiology, Nutr

Compared to the liver, we observed that the kidney has: (1) similar increased use of energy-related metabolites and production of urea cycle and ammonia-related intermediates, suggesting a shared catabolism in AKI, and (2) higher pools of energy metabolism intermediates in AKI

For instance, it may affect the metabolism of drugs that are substrates of the cytochrome P450 enzyme system, potentially altering their efficacy or toxicity

Keep in mind that there is ongoing discussion about what reference ranges to use for mycotoxin testing, so its important to follow each labs standard ranges.

Furthermore, hospital pharmacies often manage the dispensing of injectable medications requiring specific storage and handling, which is the case for many GLP-1 receptor agonists